ClinicalTrials.gg
CompletedNCT01104766Updated Oct 29, 2018Results posted

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

A Phase 3 interventional study of Cariprazine and Aripiprazole in Schizophrenia, sponsored by Forest Laboratories. Completed at 58 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-10-29.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
4th of 23
617 · median 129
Started
2010
with 2 others
Phase 3
8 of 23
1 open now
Registered
5th of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 4th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 5th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Acute Schizophrenia
  • Psychotropic Drugs
  • Aripiprazole
  • Antipsychotic Agents
  • Mental Disorders
  • Dopamine Agents
  • Central Nervous System Agents
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have provided prior to any study specific procedures
  • Patients currently meeting the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID)
  • Patients with normal physical examination, laboratory, vital signs,and/ or (ECG)
  • Current psychotic episode (schizophrenia exacerbation) \< 2 weeks duration at Visit 1
  • Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS) total score ≥ 80 and ≤ 120
  • CGI-S score ≥ 4

Exclusion criteria

Exclusion Criteria:

  • Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders
  • Bipolar I and II disorder
  • Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders
  • axis II disorder of sufficient severity to interfere with participation in this study
  • Women who are pregnant or breast feeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Cariprazine 3mg

    Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

    Drug: Cariprazine

  • Experimental
    Cariprazine 6mg

    Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

    Drug: Cariprazine

  • Active comparator
    Aripiprazole 10mg

    Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

    Drug: Aripiprazole

  • Placebo comparator
    Placebo

    Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

    Drug: Placebo

Interventions

  • Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

    Also known as: RGH-188

  • Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

  • DrugPlacebo

    Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

06

What researchers measure

Primary outcomes

  1. Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.

    The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change from baseline score indicates improvement.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Measurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S)

    The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change from baseline score indicates improvement.

    Time frame: Baseline to Week 6

07

Results

Posted Oct 29, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mg
Started153155157152
Completed9510497114
Not completed58516038
Withdrew: Did not meet inc/exc criteria1000
Withdrew: Adverse event17152014
Withdrew: Lack of efficacy2015148
Withdrew: Protocol violation2000
Withdrew: Withdrawal by subject17192515
Withdrew: Lost to follow-up1211

Outcome measures

PrimaryMeasurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.

The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change from baseline score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a Scale
Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.
Units on a ScalePlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mg
Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.-14.3 ± 1.5-20.2 ± 1.5-23.0 ± 1.5-21.2 ± 1.4
Statistical analysis
  • Placebo vs Cariprazine 3.0 mg · ANCOVA · p = 0.0044 · Mean difference (final values): -6.0 · 95% CI -10.1 to -1.9
  • Placebo vs Cariprazine 6.0mg · ANCOVA · p = <0.0001 · Mean difference (final values): -8.8 · 95% CI -12.9 to -4.7
  • Placebo vs Aripiprazole 10.0 mg · ANCOVA · p = 0.0008 · Median difference (final values): -7.0 · 95% CI -11.0 to -2.9
SecondaryMeasurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S)

The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change from baseline score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a Scale
Measurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S)
Units on a ScalePlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mg
Measurement of the Overall Severity of Illness: Change From Baseline in Clinical Global Impression-Severity (CGI-S)-1.0 ± 0.1-1.4 ± 0.1-1.5 ± 0.1-1.4 ± 0.1
Statistical analysis
  • Placebo vs Cariprazine 3.0 mg · ANCOVA · p = 0.0004 · Mean difference (final values): -0.4 · 95% CI -0.6 to -0.2
  • Placebo vs Cariprazine 6.0mg · ANCOVA · p = <0.0001 · Median difference (final values): -0.5 · 95% CI -0.7 to -0.3
  • Placebo vs Aripiprazole 10.0 mg · ANCOVA · p = 0.0001 · Median difference (final values): -0.4 · 95% CI -0.6 to -0.2

Adverse events

Collected over Assessed over 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/153 (0%)2/153 (1.3%)68/153 (44.4%)
Cariprazine 3.0 mg0/155 (0%)4/155 (2.6%)61/155 (39.4%)
Cariprazine 6.0mg2/157 (1.3%)7/157 (4.5%)71/157 (45.2%)
Aripiprazole 10.0 mg0/152 (0%)4/152 (2.6%)61/152 (40.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mg
Psychotic disorderPsychiatric disorders0/1532/1550/1570/152
Social stay hospitalizationSurgical and medical procedures0/1530/1551/1571/152
BronchitisRespiratory, thoracic and mediastinal disorders0/1530/1550/1571/152
DepressionPsychiatric disorders0/1530/1550/1571/152
Toxicity to various agentsInjury, poisoning and procedural complications0/1530/1550/1571/152
Artropod biteInjury, poisoning and procedural complications1/1530/1550/1570/152
PneumoniaRespiratory, thoracic and mediastinal disorders1/1530/1550/1570/152
Schizophrenia, paranoid typePsychiatric disorders0/1531/1551/1570/152
SchizophreniaPsychiatric disorders0/1531/1550/1570/152
Supraventricular tachycardiaCardiac disorders0/1531/1550/1570/152
Most frequent other events
Most frequent other events
EventPlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mg
InsomniaPsychiatric disorders25/15321/15522/15716/152
AkathisiaNervous system disorders9/15312/15524/15711/152
HeadacheNervous system disorders17/15310/15516/15715/152
AnxietyPsychiatric disorders11/15312/15512/15712/152
AgitationPsychiatric disorders12/1533/1554/1578/152
SchizophreniaPsychiatric disorders12/1533/1554/1578/152
NauseaGastrointestinal disorders5/1533/1555/15711/152
Abdominal discomfortGastrointestinal disorders3/1531/1557/1579/152
Vaginal InfectionInfections and infestations0/563/560/570/58

Baseline characteristics

The randomized population is also the safety population.

Age, Continuous
Age, Continuous(Years)PlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mgTotal
Mean38.2 ± 11.337.9 ± 10.638.6 ± 10.639.3 ± 10.838.5 ± 10.8
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mgTotal
Male979910094390
Female56565758227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mgTotal
Hispanic or Latino325212
Not Hispanic or Latino137134133134538
Unknown or Not Reported1319191667
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine 3.0 mgCariprazine 6.0mgAripiprazole 10.0 mgTotal
White9310210199395
Black or African-American42323633143
Asian11024
Native Hawaiian or Other Pacific Islander31015
Other22318
Missing1217171662
08

Study locations

58 sites
  • Woodland International Research Group, Inc.
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest, LLC
    Springdale, Arkansas 72764, United States
  • Synergy Clinical Research of Escondido
    Escondido, California 92025, United States
  • Excell Research, Inc
    Oceanside, California 92056, United States
  • Clinical Innovations, Inc.
    Riverside, California 92506, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • Collaborative Neuroscience Network, Inc.
    Torrance, California 90502, United States
  • Colorado Clinical Trials, Inc.
    Littleton, Colorado 80130, United States
  • Comprehensive Clinical Development, Inc.
    Washington, District of Columbia 20016, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Hawaii Clinical Research Center
    Honolulu, Hawaii 96813, United States
  • Uptown Research Institute, LLC
    Chicago, Illinois 60640, United States
  • Alexian Brothers Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Millennium Psychiatric Associates, LLC
    Creve Coeur, Missouri 63141, United States
  • CRI Worldwide, LLC
    Willingboro, New Jersey 08046, United States
  • Windsor-Laurelwood Center for Behavioral Medicine
    Willoughby, Ohio 44094, United States
  • Vanderbilt Psychiatric Hospital
    Nashville, Tennessee 37212, United States
  • Claghorn-Lesem Research Clinic, Ltd.
    Houston, Texas 77008, United States
  • Pacific Institute of Medical Sciences
    Bothell, Washington 98011, United States
  • Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia", Clinica X Psihiatrie
    Bucuresti, 041914, Romania
  • Spitalul Clinic de Psihiatrie 'Prof. Dr. Alexandru Obregia', Clinica III Psihiatrie
    Bucuresti, 41914, Romania
  • Spitalul Clinic de Psihiatrie 'Prof. Dr. Alexandru Obregia', Clinica VIII Psihiatrie
    Bucuresti, 41914, Romania
  • Spitalul Clinic Judetean de Urgenta Cluj, Clinica de Psihiatrie III
    Cluj-Napoca, 400012, Romania
  • Spitalul Clinic de Neuropsihiatrie Craiova, Clinica II Psihiatrie
    Craiova, 200620, Romania
  • Spitalul Clinic Militar de Urgenta, 'Dr. Stefan Odobleja' Clinical de Psihiatrie
    Craiova, 200745, Romania
  • Spitalul Judetean de Urgenta Piatra Neamt
    Piatra Neamt, 610136, Romania
  • Spitalul Judetean de Urgenta Pitesti, Clinica de Psihiatrie
    Pitesti, 110069, Romania
  • Spitalul de Psihiatrie Dr. Gheorghe Preda" Sibiu
    Sibiu, 550082, Romania
  • Spitalul Judetean de Urgenta Targoviste, Sectia Psihiatrie
    Targoviste, 130086, Romania
  • Spitalul Clinic Judetean Mures, Clinica Psihiatrie I
    Targu Mures, 540142, Romania
  • Spitalul Clinic Judetean de Urgenta Timisoara, Sectia Clinica de Psihiatrie "eduard Pamfil"
    Timisoara, 300736, Romania
  • Healthcare Institution "Moscow Regional Mental Hospital #5"
    Orekhovo-Zuyevo, Moscow Region 142601, Russian Federation
  • State Healthcare Institution <Arkhangelsk Regional Clinical Psychiatric Hospital>
    Arkhangelsk, 163530, Russian Federation
  • State Healthcare Institution "Regional Clinical Specialized Psychoneurological Hospital #1"
    Chelyabinsk, 454087, Russian Federation
  • State Educational Institution of High Professional Education "Chita State Medical Academy of Roszdrav"
    Chita, 672090, Russian Federation
  • St. Petersburg State Healthcare Institution "Mental Hospital #1 named after P.P Kashchenko"
    Gatchina, 188357, Russian Federation
  • Municipal Healthcare Institution "City Clinical Hospital #2 named after V.I Razumovsky"
    Saratov, 410028, Russian Federation
  • State Healthcare Institution "Saratov Saint Sophia Regional Mental Hospital"
    Saratov, 410060, Russian Federation
  • St. Petersburg State Healthcare Institution "St. Nicholas the Wonderworker Mental Hospital"
    St. Petersburg, 190121, Russian Federation
  • Federal State Budget Institution "St. Petersburg scientific-research psychoneurological Institute named after V.M Bekhterev" of the Ministry of Health and Social Development of the Russian Federation, Department of biological therapy of mental patients
    St. Petersburg, 192019, Russian Federation
  • State institution "St. Petersburg scientifis-research psychoneurologic Institute of RosZdrav named after V.M Bekhterev"
    St. Petersburg, 192019, Russian Federation
  • Federal State Budget Institution "St. Petersburg scientific-research psychoneurological Institute named after V.M Bekhterev" of the Minitstry of Health and Social Development of the Russian Federation
    St. Petersburg, 1922019, Russian Federation
  • St. Petersburg State Healthcare Institution "City Mental Hospital #6 (hospital and Dispensary)"
    St. Petersburg, 193167, Russian Federation
  • St. Petersburg State Healthcare Institution "City Mental Hospital #3 named after I.I Skvortsov-Stepanov", department #7
    St. Petersburg, 197341, Russian Federation
  • Regional State Healthcare Institution "Tomsk Clinical Mental Hospital"
    Tomsk, 634014, Russian Federation
  • Communal Institution of Kyiv Regional Council: Regional Psychiatric-Narcological Medical Association, Department #2 and #14
    Village Glevakha, Kyiv 08613, Ukraine
  • I.I. Mecnikov Regional Clinical Hospital, Regional Center of Psychosomatic Pathology
    Dnipropetrovsk, 49005, Ukraine
  • Ukraine State Scientific and Research Institute of Medical and Social Problems of Disabiolity, Department of Psychoneurology, Psychotherapy and Medical Psychology
    Dnipropetrovsk, 49027, Ukraine
  • Regional Clinical Psychiatric Hospital Department #11, M. Gorkyy Donetsk National Medical University, Chair of Psychiatry and Medical Psychology
    Donetsk, 83008, Ukraine
  • Kharkiv Regional Clinical Psychiatric Hospital #3, Department #4, Department #14
    Kharkiv, 61068, Ukraine
  • State Institution: Institute of Neurology, Psychiatry and Narcology of the AMS of Ukraine, Department of Borderline Psychic Pathology
    Kharkiv, 61068, Ukraine
  • Kherson Regional Psychiatric Hospital, Department #3
    Kherson, 73488, Ukraine
  • Kyiv City Clinical Psychoneurological Hospital #1, Center of Novel Treatment Methods and Rehabilitation of Psychotic Conditions
    Kyiv, 04080, Ukraine
  • Communal Institution: Lviv Regional Clinical Psychiatric Hospital, Department #3 (male), Department #10 (female)
    Lviv, 79021, Ukraine
  • O.F. Maltsev Poltava Regional Clinical Psychiatric Hopspital, Department #3B, State Institution of Higher Education of Ukraine: Ukranian Medical Stomatological Academy, Chair of Psychiatry, Narcology and Medical Psychology
    Poltava, 36006, Ukraine
  • Crimean Republican Institution: Clinical Psychiatric Hospital #1, Female Psychiatric Department #2, Male Psychiatric Department #1, S.I. Georgiyevskyy Crimean State Medical University, Chair of Psychiatry, Psychotherapy and Narcology
    Simferopol, 95006, Ukraine
  • O.I. Yuschenko Vinnytsya Regional Psychoneurological Hospital, Department #10, Department #14, M.I. Pyrogov Vinnytsya National Medical University, Chair of Psychiatry and Narcology
    Vinnytsya, 49005, Ukraine
09

References and documents

Publications

  • Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016 Jan;77(1):109-15. doi: 10.4088/JCP.15m10192. PubMed 26845266 ↗
  • Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017 Nov;32(6):319-328. doi: 10.1097/YIC.0000000000000187. PubMed 28692485 ↗
  • Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, Nemeth G, Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017 Aug 24;17(1):305. doi: 10.1186/s12888-017-1459-z. PubMed 28836957 ↗
  • Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Nemeth G, Meltzer HY. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015 Dec;76(12):e1574-82. doi: 10.4088/JCP.15m09997. PubMed 26717533 ↗
  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. PubMed 34091867 ↗
  • Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley WR, Nemeth G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr Dis Treat. 2021 Apr 7;17:957-970. doi: 10.2147/NDT.S301225. eCollection 2021. Erratum In: Neuropsychiatr Dis Treat. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858. PubMed 33854317 ↗
  • Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Nemeth G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019 Jan;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008. Epub 2018 Nov 20. PubMed 30470662 ↗
  • Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Nemeth G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018 Feb;23(1):39-50. doi: 10.1017/S1092852917000220. Epub 2017 May 8. PubMed 28478771 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in Dec 2011, 19 months.

Results were first posted in Oct 2018, 6 years 10 months after primary completion. A results delay was requested in Dec 2011.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 19 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2010
First posted
Apr 15, 2010
StartActual
Apr 23, 2010
Primary completionActual
Dec 20, 2011
CompletionActual
Dec 20, 2011
Results delay requested
Dec 30, 2011
Results first posted
Oct 29, 2018
Last update
Oct 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01104766
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2010
Start date
Apr 23, 2010
Primary completion
Dec 20, 2011
Completion
Dec 20, 2011
Results posted
Oct 29, 2018
Last update
Oct 29, 2018

Study contacts

Raffaele Migliore, MA
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion